EIO Biomedical
Postsurgical Adhesion Prevention
Health Tech & Life Sciences
Non Active, Jan 2023 ceased to operate
Company Overview
Snapshot
Founded in November 2016 by Yair Pilpel, EIO Biomedical operated with 1–10 employees. The company raised $1.5 million across two funding rounds from three investors. In January 2019, the company secured funding from NGT3 and Israel Innovation Authority.
Business overview
EIO Biomedical was a biotechnology company focused on developing a medical device to prevent postsurgical adhesions. Its core product, the FuseX system, was designed to deliver a sprayable adhesion barrier by converting blood plasma into an enzymatic combination that reduces adhesion formation. The company targeted the healthcare industry, specifically providers, with its medical device technology for use in operating rooms and surgical settings.
Company Intelligence Q&A
- What is EIO Biomedical's primary focus?
- EIO Biomedical focused on developing a medical device for the prevention of postsurgical adhesions, aiming to alleviate problems associated with surgical sewing.
- When was EIO Biomedical founded?
- EIO Biomedical was founded in November 2016.
- Who founded EIO Biomedical?
- EIO Biomedical was founded by Yair Pilpel.
- What is the status of EIO Biomedical?
- EIO Biomedical is non-active and ceased to operate in January 2023.
- What was the total capital raised by EIO Biomedical?
- EIO Biomedical raised a total of $1.5 million across two funding rounds.